Page 1

PRESS RELEASE ● ● affi med Affimed Reports Second Quarter 2021 Financial Results and Highlights Operational Progress AFM13 monotherapy : Enrollment is on track and expected to be completed in the first half of 2022 . AFM13 combination with NK cells : All three dose escalation cohorts are fully enrolled with no dose limiting toxicities observed ; additional patients are being enrolled at the highest dose level to confirm safety and generate additional efficacy data ; data update expected at a scientific conference in Q4 2021 . AFM24 monotherapy : Based on current data , doses used in cohorts 5 ( 320 mg ) and 6 ( 480 mg ) are pharmacologically active ; no classic EGFR related side effects observed to date ; dose expansion phase expected to start in 2021 . AFM24 combination with anti PD - L1 checkpoint inhibitor : Clinical trial of AFM24 with atezolizumab ( TecentriqⓇ ) on track to start in 2021 . AFM24 combination with NK cells : Clinical trial of AFM24 with NKGen Biotech's SNK01 NK autologous cell therapy on track to start in 2021 . Cash and cash equivalents as of June 30 , 2021 , were approximately € 222.7 million with anticipated cash runway into the second half of 2023 . ● Conference call and webcast scheduled for September 8 , 2021 , at 8:30 a.m. EDT . Heidelberg , Germany , September 8 , 2021 - Affimed N.V. ( Nasdaq : AFMD ) , a clinical stage immuno - oncology company committed to giving patients back their innate ability to fight cancer , today reported financial results for the quarter ended June 30 , 2021 , and provided an update on clinical and corporate progress . " We are pleased with the continued progress in our development of AFM13 , AFM24 and AFM28 , " said Adi Hoess , CEO of Affimed . " By the end of this year , we expect to report additional data from AFM13-104 , progress our parallel development strategy for AFM24 and disclose the details of our AFM28 program . We expect our broad development pipeline will generate an ongoing stream of data over the next several quarters , " he concluded .